Omega Alpha SPAC
- Healthcare, Biotech
Otello Stampacchia, PhD serves as our Chief Executive Officer and the Chairman of our board of directors . Dr. Stampacchia is founder, Managing Director, and a member of the investment committee at Omega. Dr. Stampacchia currently serves on the board of directors of public companies: Kronos Bio (Nasdaq: KRON) (since May 2018), Morphic Therapeutic (Nasdaq: MORF) (since September 2018), and Replimune (Nasdaq: REPL) (since September 2015), and private companies: Amunix Pharmaceuticals, Inc. (since March 2020) and Scorpion Therapeutics (since October 2020). Dr. Stampacchia has also previously served on the boards of ESSA Pharma, Inc. from January 2015 to October 2019, Median Technologies SA from September 2014 to January 2020, Nuvation Bio, Inc. from February 2019 to September 2020 and Gossamer Bio, Inc. from January 2018 to September 2019. Prior to founding Omega, Dr. Stampacchia was in charge of life sciences direct investments and diligence for healthcare venture fund of fund investments at AlpInvest Partners (now part of The Carlyle Group). Before AlpInvest Partners, he was the portfolio manager of the Lombard Odier Immunology Fund, an investment vehicle in Geneva, Switzerland, investing in public and private healthcare companies worldwide. Previously, Dr. Stampacchia was a member of the HealthCare corporate finance and M&A team at Goldman Sachs. Before Goldman, he helped co-found the healthcare investment activities at Index Securities (now Index Ventures). Dr. Stampacchia has a PhD in Molecular Biology from the University of Geneva, holds a European Doctorate in Biotechnology from the EU, and obtained an MSc in Genetics from the University of Pavia.
We believe that Dr. Stampacchia’s broad operational and transactional experience, and his position as Chief Executive Officer, make him well qualified to serve as the Chairman of our board of directors.
Michelle Doig serves as our President and a director on our board of directors. Since December 2016, Ms. Doig has been a Partner at Omega. Ms. Doig also currently serves on the board of directors of Nuvation Bio (since June 2019). Prior to Omega, Ms. Doig was Director of Corporate Finance at Third Rock Ventures from November 2013 until December 2016, where she supported numerous portfolio companies with financing strategy and execution. Prior to joining Third Rock Ventures, Ms. Doig was Principal, Corporate Finance, at Abingworth (in both London and Boston offices). She was also a life sciences investment banker with Lehman Brothers International in London, JP Morgan/H&Q in New York and Morgan Stanley in Toronto and New York. Ms. Doig graduated with an Honors degree in Business Administration from the Ivey School of Business at the University of Western Ontario in London.
We believe that Ms. Doig’s broad operational and transactional experience make her well qualified to serve as a member of our board of directors.
Francesco Draetta, CFA, FRM, CAIA serves as our Chief Financial Officer . Since August 2016, Mr. Draetta has been a Partner at Omega. Mr. Draetta currently serves on the board of directors of private company Chord Therapeutics SA (since October 2020). Prior to joining Omega, from August 2015 to August 2016, Mr. Draetta was an Analyst at Brookside Mezzanine Partners, a mezzanine fund investing in subordinated debt and minority equity in small- to mid-size companies throughout the U.S., where he focused on due diligence, deal management, and investor relations. Prior to Brookside Mezzanine Partners, Mr. Draetta was an Associate at Commonfund Capital (CCI), the private capital arm of Commonfund, where he focused on due diligence, manager selection, investment management, and investor relations for CCI’s private equity, venture capital, and natural resources programs. He began his career at Omega as an Analyst. Mr. Draetta graduated cum laude from the Isenberg School of Management at the University of Massachusetts Amherst with a BBA in Finance and Operations Management. He is also a CFA charterholder, a CAIA charterholder, and a Certified FRM.
Vincent Ossipow, PhD, CFA serves as our Chief Scientific Officer . Since April 2014, Dr. Ossipow has been a Partner at Omega. Dr. Ossipow currently serves on the board of directors of Immunic Therapeutics (Nasdaq: IMUX) (since September 2016) and private companies eTheRNA Immunotherapies Nv (since March 2016) and FoRx Therapeutics AG (since October 2019). Dr. Ossipow has also previously served on the boards of BioInvent International AB from May 2016 to May 2020 and Kuros Biosciences from August 2015 to May 2016. Previously, Dr. Ossipow worked at Sectoral Asset Management, a healthcare institutional investor, as a Partner for private investments. Prior to that, he was research fellow at the University of Geneva, studying the molecular basis of brain function, and also acted as Sectoral Asset Management’s Chief Scientific Officer. Previously, he worked at Pictet Bank as a research analyst for biotechnology equities and as a co-manager of the Pictet Biotech Fund, a listed investment vehicle. Dr. Ossipow trained as a postdoctoral fellow in Geneva (Hoffman-La-Roche and Human Frontier Science Program fellow) and at the National Cancer Institute in Bethesda, MD. He completed a Certificate in International Finance and Global Markets at the Georgetown University School of Business and holds an MS in Computational Sciences, an MS in Molecular Biology, and a PhD in Molecular Biology, all from the University of Geneva. He is also a CFA charterholder.
Daniel Lynch has agreed to serve on our board of directors following the completion of this offering. Mr. Lynch currently serves as chairman of the board of directors of bluebird bio, Inc. (since May 2011), Blueprint Medicines Corp. (since November 2012), Xilio Therapeutics, Inc. (since June 2020), Surface Oncology, Inc. (since January 2017), SpringWorks Therapeutics, Inc. (since September 2017) and Translate Bio, Inc. (since September 2012), as a director on the board of directors of Nextech Invest Limited (since June 2020) and as an advisor at Third Rock Ventures. Previously, Mr. Lynch served as chief executive and chief financial officer of ImClone Systems Corporation, where he led ImClone through a significant turnaround, helping to restore the company’s reputation and to secure FDA approval of ERBITUX (Cetuximab), a novel cancer treatment. Prior to that, he served in various financial positions at Bristol-Myers Squibb over a 15-year tenure. He also served on the board of directors and the audit committee of U.S. Oncology, Inc. for five years until December 2010, when it was acquired by McKesson. Mr. Lynch previously served as a member of the board of directors of Sesen Bio Inc. until May 2020 and BIND Therapeutics until August 2016. Mr. Lynch received his B.A. in mathematics from Wesleyan University and his M.B.A. from the Darden Graduate School of Business Administration at the University of Virginia.
We believe that Mr. Lynch’s experiences as a senior executive and service on the boards of directors of other life sciences companies qualify him to serve as a member of our board of directors.
Jan van de Winkel, PhD has agreed to serve on our board of directors following the completion of this offering. Dr. van de Winkel is a co-founder of Genmab and served as President, Research & Development and Chief Scientific Officer of the company until his appointment as President & Chief Executive Officer in 2010. Dr. van de Winkel has more than 25 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to Genmab. He is the author of over 300 scientific publications and has been responsible for over 150 patents and pending patent applications. Dr. van de Winkel holds a professorship of immunotherapy at Utrecht University. He is chairman of the board of directors of Hookipa Pharma Inc, and member of the board of directors of Leo Pharma A/S, both roles which he has held since 2017. Dr. van de Winkel previously served as a member of the board of directors of Forward Pharma A/S until May 2017. He holds M.S. and Ph.D. degrees from the University of Nijmegen.
We believe that Dr. van de Winkel’s experience in managing biotechnology and pharmaceutical companies, as well as his experience as a director of such companies, make him well qualified to serve as a member of our board of directors.
Martin Babler has agreed to serve on our board of directors following the completion of this offering. Since September 2020, Mr. Babler has served on the board of directors of Neoleukin Therapeutics, Inc. (Nasdaq: NLTX). Mr. Babler was chief executive officer of Principia BioPharma, Inc., a start-up company established to develop novel small molecule drugs for autoimmune diseases, from April 2011 until its acquisition by Sanofi in September 2020. From September until October 2020, he served as an adviser to Principia BioPharma, Inc. Mr. Babler also served on the board of directors of ZS Pharma, Inc. from February to December 2015. From December 2007 to April 2011, Mr. Babler was chief executive officer of Talima Therapeutics, Inc., a privately held drug delivery company. Prior to joining Talima, from 1998 to 2006, Mr. Babler was Vice President of Immunology Sales and Marketing, built and led the Commercial Development organization and initially served as Director of Cardiovascular Marketing, at Genentech, Inc. Prior to joining Genentech, Mr. Babler held various roles of increasing responsibility in sales, sales management, marketing and business development with Eli Lilly and Company. Mr. Babler holds a degree in pharmacy/pharmacology from the ETH in Zurich, Switzerland and has completed the Executive Development Program at Kellogg Graduate School of Management.
We believe that Mr. Babler’s experience in managing biotechnology and pharmaceutical companies make him well qualified to serve as a member of our board of directors.
Joseph Slattery has agreed to serve on our board of directors following the completion of this offering. Mr. Slattery currently serves on the board of directors of Replimune (since October 2017), Morphic Therapeutic (since May 2019) and CVRx, Inc. (since October 2008). He previously served as executive vice president and CFO of TransEnterix, Inc. until December 2019, as executive vice president and CFO at Baxano Surgical Inc., and as CFO and senior vice president of finance and information systems of Digene Corp. He has served on the board of directors of Micromet, Inc., TranS1, Inc., and Exosome Diagnostics, Inc. Mr. Slattery earned his bachelor’s degree in accountancy from Bentley University and is a certified public accountant.
We believe that Mr. Slattery’s experience in managing healthcare companies, as well as his experience as a public company director, make him well qualified to serve as a member of our board of directors.